Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase

Journal of Medicinal Chemistry

Volumn 40, Issue 2, 1997, Pages 192-200

  Leonard, Daniele M ^a   Shuler, Kevon R ^a   Poulter, Cynthia J ^a   Eaton, Scott R ^a   Sawyer, Tomi K ^a   Hodges, John C ^a   Su, Ti Zhi ^a   Scholten, Jeffrey D ^a   Gowan, Richard C ^a   Sebolt Leopold, Judith S ^a   Doherty, Annette M ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLHISTIDYL(O BENZYLTYROSYL)(O BENZYLSERYL)TRYPTOPHYL DEXTRO ALANINAMIDE; FARNESYL TRANS TRANSFERASE; PENTAPEPTIDE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CONCENTRATION RESPONSE; ENZYME INHIBITION; FEMALE; NONHUMAN; ONCOGENE RAS; PROTEIN PROCESSING; STRUCTURE ACTIVITY RELATION; XENOPUS;

ALKYL AND ARYL TRANSFERASES; AMINO ACIDS; ANIMALS; BINDING SITES; CYSTEINE; ENZYME INHIBITORS; INSULIN ANTAGONISTS; OLIGOPEPTIDES; OOCYTES; PHOSPHATES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFERASES; XENOPUS;

EID: 15444339430     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960602m     Document Type: Article

References (55)

1. Manne, V.; Roberts, D.; Tobin, A.; O'Rourke, E.; DeVirgilio, M.; Meyers, C.; Ahmed, N.; Kurz, B.; Resh, M.; Rung, H.-F.; Barbacid, M. Identification and preliminary characterization of protein-cysteine farnesyl transferase. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 7541-7545.
2. Schaber, M. D.; O'Hara, M. B.; Garsky, V. M.; Mosser, S. D.; Bergstrom, J. D.; Moores, S. L.; Marshall, M. S.; Friedman, P. A.; Dixon, R. A. F.; Gibbs, J. B. Polyisoprenylation of Ras in vitro by a farnesyl-protein transferase. J. Biol. Chem. 1990, 265, 14701-14704.
3. Reiss, Y.; Seabra, M. C.; Goldstein, J. L.; Brown, M. S. Purification of ras farnesyl protein transferase. Methods: Companion Methods Enzymol. 1990, 1, 241-245.
4. Reiss, Y.; Goldstein, J. L.; Seabra, M. C.; Casey, P. J.; Brown, M. S. Inhibition of purified p21 ras farnesyl:protein transferase by CysAAX tetrapeptides. Cell 1990, 62, 81-88.
5. Casey, P. J.; Thissen, J. A.; Moomaw, J. F. Enzymatic modification of protein with a geranylgeranyl isoprenoid. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 8631-8635.
6. Yokoyama, K.; Goodwin, G.; Ghomsashchi, F.; Glomset, J. A.; Gelb, M. H. A protein geranylgeranyl transferase from bovine brain: implications for protein prenylation specificity. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 5302-5306.
7. Chen, W.-J.; Andres, D. A.; Goldstein, J. L.; Russell, D. W.; Brown, M. S. cDNA cloning and expression of the peptide-binding β subunit of rat p21ras farnesyltransferase, the counterpart of yeast DPR1/RAM1. Cell 1991, 66, 327-334.
8. Chen, W.-J.; Andres, D. A.; Goldstein, J. L.; Brown, M. S. Cloning and expression of a cDNA encoding the α-subunit of rat p21ras protein farnesyltransferase. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 11368-11372.
9. Kohl, N. E.; Diehl, R. E.; Schaber, M. D.; Rands, E.; Soderman, D. D.; He, B.; Moores, S. L.; Pompliano, D. L.; Ferro-Novick, S.; Powers, S.; Thomad, K. A.; Gibbs, J. B. Structural homology among mammalian and saccharomyces cerevisiae isoprenyl-protein transferase. J. Biol. Chem. 1991, 266, 18884-18888.
10. Seabra, M. C.; Reiss, Y.; Casey, P. J.; Brown, M. S.; Goldstein, J. L. Protein farnesyltransferase and geranylgeranyltransferase share a common a subunit. Cell 1991, 65, 429-434.
11. Casey, P. J.; Solski, P. A.; Der, C. J.; Buss, J. E. p21ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 8323-8327.
12. Glomset, J.; Gelb, M.; Farnsworth, C. The prenylation of proteins. Curr. Opin. Lipidol. 1991, 2, 118-124.
13. Hancock, J. F.; Magee, A. I.; Chids, J. E.; Marshall, C. J. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989, 57, 1167-1177.
14. Ashby, M. N.; King, D. S.; Rine, J. Endoproteolytic processing of a farnesylated peptide in vitro. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 4613-4617.
15. Ma, Y.-T.; Rando, R. R. A microsomal endoprotease that specifically cleaves isoprenylated peptides. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 6275-6279.
16. Akopyan, T. N.; Couedel, Y.; Beaumont, A.; Fournie-Salurki, M.-C.; Roques, B. P. Cleavage of farnesylated COOH-teminal heptapeptide of mouse N-ras by brain microsomal membranes: Evidence for a carboxypeptidase which specifically removes the COOH-terminal methionine. Biochem. Biophys. Res. Commun. 1992, 187, 1336-1342.
17. Clarke, S.; Voge, J. P.; Deschenens, R. J.; Stock, J. Posttranslational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxyl methyl transferases. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4643-4647.
18. Perez-Sala, D.; Tan, E. W.; Canada, F. J.; Rando, R. R. Methylation and demethylation reactions of guanine nucleotide-binding proteins of retinal rod outer segments. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 3043-3046.
19. Barbacid, M. The ras oncogene. Annu. Rev. Biochem. 1987, 56, 779-828.
20. Cox, A. D.; Der, C. J. The ras/cholesterol connection: Implications for ras oncogenicity. Crit. Rev. Oncogen. 1992, 3, 365-400.
21. Bos, J. L. ras Oncogenes in human cancer. A review. Cancer Res. 1989, 49, 4682-4689.
22. Goldstein, J. L.; Brown, M. S.; Stradley, S. J.; Reiss, Y.; Gierasch, L. M. Non-farnesylated tetrapeptide inhibitors of protein farnesyl transferase. J. Biol. Chem. 1991, 266, 15575-15578.
23. Kohl, N. E.; Mosser, S. D.; deSolms, S. J.; Giuliani, E. A.; Pompliano, D. L.; Graham, S. L.; Smith, R. L.; Scolnick, E. M.; Oliff, A.; Gibbs, J. B. Selective inhibition of ras dependent transformation by a farnesyl transferase inhibitor. Science 1993, 260, 1934-1937.
24. Graham, S. L.; deSolms, S. J.; Giuliani, E. A.; Kohl, N. E.; Mosser, S. D.; Oliff, A. I.; Pompliano, D. L.; Rands, E.; Breslin, M. J.; Deana, A. A.; Garsky, V. M.; Scholx, T. H.; Gibbs, J. B.; Smith, R. L. Pseudopeptide inhibitors of ras farnesyl protein transferase. J. Med. Chem. 1994, 37, 725-732.
25. Kohl, N. E.; Wilson, F. R.; Mosser, S. D.; Giuliani, E.; deSolms, S. J.; Conner, M. W.; Anthony, N. J.; Holtz, W. J.; Gomez, R. P.; Lee, T.-J.; Smith, R. L.; Graham, S. L.; Hartman, G. D.; Gibbs, J. B.; Oliff, A. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 9141-9145.
26. Prendergast, G. C.; Davide, J. P.; deSolms, S. J.; Giuliani, E. A.; Graham, S. L.; Gibbs, J. B.; Oliff, A.; Kohl, N. E. Farnesyl transferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin skeleton. Mol. Cell. Biol. 1994, 14, 4193-4202.
27. Garcia, A. M.; Rowell, C.; Ackerman, K.; Kowalezyck, J. J.; Lewis, M. D. Peptidomimetic inhibitors of ras farnesylation and function in whole cells. J. Biol. Chem. 1993, 268, 18415-18418.
28. Cox, A. D.; Garcia, A. M.; Westwick, J. K.; Kowalezyck, J. J.; Lewis, M. D.; Brenner, D. A.; Der, C. J. The CAAX peptidomimetic compound B581 specifically blocks farnesylation but not geranylgeranylated or myristylated, oncogenic ras signalling and transformation. J. Biol. Chem. 1994, 269, 19203-19206.
29. Nagasu, T.; Yoshimatsu, K.; Rowell, C.; Lewis, M. D.; Garcia, A. M. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. 1995, 55, 5310-5314.
30. Qian, Y.; Vogt, A.; Sebti, S. M.; Hamilton, A. D. Design ans synthesis of non-peptide ras CAAX mimetics as potent farnesyl transferase inhibitors. J. Med. Chem. 1996, 39, 217-223.
31. Leftheris, K.; Kline, T.; Vite, G. D.; Cho, V. H.; Bhide, R. S.; Patel, D. V.; Patel, M. M.; Schmidt, R. J.; Weller, H. N.; Andahazv, M. L.; Carboni, J. M.; Gullo-Brown, J. L.; Lee, F. Y. F.; Ricca, C.; Rose, W. C.; Yan, N.; Barbacid, M.; Hunt, J. T.; Meyers, C. A.; Seizinger, B. R.; Zahler, R.; Manne, V. Development of highly potent inhibitors of ras farnesyl transferase possessing cellular and in vivo activity. J. Med. Chem. 1996, 39, 224-236.
32. James, G. L.; Goldstein, J. L.; Brown, M. S.; Rawson, T. E.; Somers, T. C.; McDowell, R. S.; Crowley, C. W.; Lucas, B. K.; Levinson, A. D.; Marsters, J. C., Jr. Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. Science 1993, 260, 1937-1942.
33. 2X peptidomimetics. J. Biol. Chem. 1993, 268, 20695-20698.
34. Qian, Y.; Blaskovich, M. A.; Saleem, M.; Seong, C. M.; Wathen, S. P.; Hamilton, A. D.; Sebti, S. M. Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyl transferase. J. Biol. Chem. 1994, 269, 12410-12413.
35. Qian, Y.; Blaskovich, M. A.; Seong, C.-M.; Vogt, A.; Hamilton, A. D.; Sebti, S. M. Peptidomimetic inhibitors of p21ras farnesyl transferase: hydrophobic functionalization leads to disruption of p21ras membrane association in whole cells. Bioorg. Med. Chem. Lett. 1994, 4, 2579-2584.
36. Lerner, E. C.; Qian, Y.; Blaskovich, M. A.; Fossum, R. D.; Vogt, A.; Sun, J.; Cox, A. D.; Der, C. J.; Hamilton, A. D.; Sebti, S. M. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic ras signaling by inducing cytoplasmic accumulation of inactive ras-raf complex. J. Biol. Chem. 1995, 270, 26802-26806.
37. Hunt, J. T.; Lee, V. G.; Leftheris, K.; Seizinger, B.; Carboni, J.; Mabus, J.; Ricca, C.; Yan, N.; Manne, V. Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase. J. Med. Chem. 1996, 39, 353-358.
38. Kowalczyk, J. J.; Ackermann, K.; Garcia, A. M.; Lewis, M. D. Phenolic replacements for cysteine in farnesyltransferase inhibitors based on CVFM. Bioorg. Med. Chem. Lett. 1995, 5, 3073-3078.
39. Bishop, W. R.; Bond, R.; Petrin, J.; Wang, L.; Patton, R.; Doll, R.; Njoroge, G.; Catino, J.; Schwartz, J.; Windsor, W.; Syto, R.; Schwartz, J.; Carr, D.; James, L.; Kirschmeier, P. Novel tricyclic inhibitors of farnesyl protein transferase: biochemical characterization and inhibition of ras modification in transfected Cos cells. J. Biol. Chem. 1995, 270, 30611-30618.
40. (a)Leonard, D. M.; Eaton, S. R.; Sawyer, T. K.; Bolton, G.; Hodges, J.; Gowan, R.; Sebolt-Leopold, J. S. Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras:farnesyltransferase. Presented at the 207th National Meeting of the American Chemical Society, San Diego, CA, March 1994; MEDI 281.
41. (b) Leonard, D. M.; Eaton, S. R.; Sawyer, T. K.; Doherty, A. M.; Bolton, G.; Hodges, J.; Scholten, J.; Gowan, R.; Sebolt-Leopold, J. S. Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras: farnesyltransferase. In Peptides 1994: Proceedings of the Twenty-Third European Peptide Symposium; Maia, H. L. S., Ed.; ESCOM Science: Leiden, The Netherlands, 1995; pp 658-659.
42. Sebolt-Leopold, J. S.; Gowan, R.; Su, T.-Z.; Leonard, D.; Sawyer, T.; Bolton, G.; Hodges, J.; Hupe, D. Inhibition of ras farnesyltransferase by a novel class of peptides containing no cysteine or thiol moieties. Proc. Am. Assoc. Cancer Res. 1994, 35, Abstract 3535.
43. Stewart, J. M.; Young, J. D. Solid Phase Peptide Synthesis; Pierce Chemical Co.: Rockford, IL, 1984.
44. The Practice of Peptide Synthesis; Bodansky, M., Bodansky, A., Eds.; Springer-Verlag: Berlin, Heidelberg, 1984.
45. Rink, H. Solid-phase synthesis of protected peptide fragments using trialkoxy-diphenyl-methyl ester. Tetrahedron Lett. 1987, 28, 3787-3790.
46. Mergler, M.; Tanner, R.; Gosteli, J.; Grogg, P. Peptide synthesis by a combination of solid phase and solution methods I: a new very acid-labile anchor group for the solid phase synthesis of fully protected fragments. Tetrahedron Lett. 1988, 29, 4005-4008.
47. Kaiser, E.; Colescott, R. L.; Bossinger, C. D.; Cook, P. I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970, 34, 595-598.
48. Scholten, J. D.; Zimmerman, K.; Oxender, M.; Sebolt-Leopold, J.; Gowan, R.; Leonard, D.; Hupe, D. J. Inhibitors of farnesyl: protein transferase: A possible cancer chemotherapeutic. Bioorg. Med. Chem. Lett. 1996, 4, 1537-1543.
49. Patel, D. V.; Gordon, E. M.; Schmidt, R. J.; Weller, H. N., Young, M. G.; Zahler, R.; Barbacid, M.; Carboni, J. M.; Gullo-Brown, J. L.; Hunihan, L.; Ricca, C.; Robinson, S.; Seizinger, B. R.; Tuomari, A. V.; Manne, V. Phosphinyl acid-based bisubstrate analog inhibitors of ras farnesyl protein transferase. J. Med. Chem. 1995, 38, 435-442.
50. Manne, V.; Van, N.; Carboni, J. M.; Tuomari, A. V.; Ricca, C. S.; Gullo-Brown, J.; Andahazy, M. L.; Schmidt, R. J.; Patel, D.; Zahler, R.; Weinmann, R.; Der, C. J.; Cox, A. D.; Hunt, J. T.; Barbacid, M.; Seizinger, B. R. Bisubstrate inhibitors of farnesyl transferase: a novel class of specific inhibitors of ras transformed cells. Oncogene 1995, 10, 1763-1779.
51. Su, T.-Z.; Logsdon, C. D.; Oxender, D. L. Chinese hamster ovary mRNA-dependent, Na+-independent L-leucine transport in Xenopus laevis oocytes. Mol. Cell. Biol. 1992, 12, 5281-5287.
52. Bolton, G. L.; Creswell, M. W.; Hodges, J. C.; Gowan, R. C.; Scholten, J.; Sebolt-Leopold, J. S. The SAR of tripeptide inhibitors of ras farnesylprotein transferase. Presented at the 209th National Meeting of the American Chemical Society, Anaheim, CA, April 1995; MEDI 032.
53. Bolton, G. L.; Creswell, M. W.; Hodges, J. C.; Gowan, R. C.; Scholten, J.; Sebolt-Leopold, J. S. Modified peptide inhibitors of ras farnesylprotein transferase. Presented at the 209th National Meeting of the American Chemical Society, Anaheim, CA, April 1995; MEDI 033.
54. Shuler, K. R.; Leonard, D. M.; Bolton, G. L.; Scholten, J.; Sebolt-Leopold, J.; Doherty, A. M. The inhibition of ras farnesyl transferase by a modified dipeptide: Structure-activity relationships. Presented at the 211th National Meeting of the American Chemical Society, New Orleans, LA, April 1996; MEDI 086.
55. Bolton, G. L.; Creswell, M. W.; Hodges, J. C.; Gowan, R. C.; Scholten, J.; Sebolt-Leopold, J. S. Modified dipeptide inhibitors of ras farnesyl transferase. Presented at the 25th National Medicinal Chemistry Symposium, Ann Arbor, MI, June 1996.